R. Wilson

679 total citations
20 papers, 502 citations indexed

About

R. Wilson is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, R. Wilson has authored 20 papers receiving a total of 502 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 8 papers in Molecular Biology and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in R. Wilson's work include PARP inhibition in cancer therapy (4 papers), Ovarian cancer diagnosis and treatment (3 papers) and Cancer Treatment and Pharmacology (3 papers). R. Wilson is often cited by papers focused on PARP inhibition in cancer therapy (4 papers), Ovarian cancer diagnosis and treatment (3 papers) and Cancer Treatment and Pharmacology (3 papers). R. Wilson collaborates with scholars based in United Kingdom, United States and France. R. Wilson's co-authors include David Y. Thomas, John Bergeron, Martina Marzioch, Adele Rowley, Johannes M. Herrmann, Roberto Solari, Mark R. Middleton, Ruth Plummer, Rebecca J. Beeken and Jane Wardle and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and British Journal of Cancer.

In The Last Decade

R. Wilson

17 papers receiving 491 citations

Peers

Countries citing papers authored by R. Wilson

Since Specialization

Citations

This map shows the geographic impact of R. Wilson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. Wilson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. Wilson more than expected).

Fields of papers citing papers by R. Wilson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R. Wilson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. Wilson. The network helps show where R. Wilson may publish in the future.

Co-authorship network of co-authors of R. Wilson

This figure shows the co-authorship network connecting the top 25 collaborators of R. Wilson. A scholar is included among the top collaborators of R. Wilson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R. Wilson. R. Wilson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	382O Inhibition of WEE1 is effective in TP53 and RAS mutant metastatic colorectal cancer (mCRC): A randomised phase II trial (FOCUS4-C) comparing adavosertib (AZD1775) with active monitoring 2021 ·Annals of Oncology ·Jenny F. Seligmann, David J. Fisher, Louise Brown, Richard Adams, Janet Graham, Philip Quirke, Susan D. Richman, Rachel Butler, Enric Domingo, Andrew Blake, Michael Braun, Fiona Collinson, Robin L. Jones, Ewan Brown, Emma De Winton, (unknown), Richard Kaplan, R. Wilson, Michel Seymour, Tim Maughan	1
2	1704P Early switch to oral antibiotic therapy in patients with low-risk neutropenic sepsis (EASI-SWITCH trial) 2021 ·Annals of Oncology ·Vicky M. Coyle, (unknown), Richard Adams, Rosemary A. Barnes, Ian Chau, Mike Clarke, (unknown), (unknown), Daniel F. McAuley, Clíona McDowell, (unknown), Ruth Plummer, Anne Thomas, R. Wilson, Ronan McMullan	0
3	A manualised weight management programme for adults with mild–moderate intellectual disabilities affected by excess weight: A randomised controlled feasibility trial (Shape Up‐LD)* 2021 ·Journal of Applied Research in Intellectual Disabilities ·Phillippa Lally, Rebecca J. Beeken, R. Wilson, Rumana Omar, Rachael Hunter, (unknown), (unknown), Michael King, Angela Hassiotis, Helen Croker	6
4	Long-term outcomes of renal transplant in recipients with lower urinary tract dysfunction 2018 ·International Journal of Surgery ·R. Wilson, Aisling E. Courtney, Dicken S. C. Ko, Alexander P. Maxwell, James McDaid	0
5	The Impact of Diet‐Induced Weight Loss on Biomarkers for Colorectal Cancer: An Exploratory Study (INTERCEPT) 2017 ·Obesity ·Rebecca J. Beeken, Helen Croker, Małgorzata Heinrich, Austin Obichere, Nick Finer, Neil Murphy, Robert Goldin, Naomi Guppy, R. Wilson, Abigail Fisher, Andrew Steptoe, Marc J. Gunter, Jane Wardle	16
6	A brief intervention for weight control based on habit-formation theory delivered through primary care: results from a randomised controlled trial 2016 ·International Journal of Obesity ·Rebecca J. Beeken, Baptiste Leurent, Victoria Vickerstaff, R. Wilson, Helen Croker, Stephen Morris, Rumana Omar, Irwin Nazareth, Jane Wardle	61
7	Body mass index and cancer screening: Findings from the English Longitudinal Study of Ageing 2014 ·Journal of Medical Screening ·Rebecca J. Beeken, R. Wilson, Laura McDonald, Jane Wardle	13
8	2FC2.1 Phase I/IIa Extension Study of PRO051/GSK2402968 in Subjects with Duchenne Muscular Dystrophy: Forty-Eight Week Safety and Efficacy Data 2011 ·European Journal of Paediatric Neurology ·Nathalie Goemans, M. Tulinius, R. Wilson, Allison Morgan, Claire Wardell, J. van Deutekom, S. de Kimpe, G. Campion	0
9	O.15 24 week follow-up data from a phase I/IIa extension study of PRO051/GSK2402968 in subjects with Duchenne muscular dystrophy 2010 ·Neuromuscular Disorders ·Nathalie Goemans, M. Tulinius, Gunnar Buyse, R. Wilson, S. de Kimpe, J. van Deutekom, G. Campion	6
10	Insulin-like growth factor receptor 1 (IGF1R) expression and survival in surgically resected non-small-cell lung cancer (NSCLC) patients 2009 ·Annals of Oncology ·Federico Cappuzzo, Giovanni Tallini, Giovanna Finocchiaro, R. Wilson, C. Ligorio, Laura Giordano, Luca Toschi, Marco Incarbone, Raffaele Cavina, Luigi Terracciano, Massimo Roncalli, Marco Alloisio, Marileila Varella‐Garcia, Wilbur A. Franklin, Armando Santoro	67
11	Randomized phase II study of decitabine in combination with carboplatin compared with carboplatin alone in patients with recurrent advanced ovarian cancer 2009 ·Journal of Clinical Oncology ·Rosalind Glasspool, Martin Gore, Gordon Rustin, Iain A. McNeish, R. Wilson, (unknown), James Paul, Melanie Mackean, Sarah Halford, S.B. Kaye, (unknown)	12
12	Vandetanib with FOLFIRI in patients with advanced colorectal adenocarcinoma: an open-label, multicenter Phase I study 2007 ·Journal of Clinical Oncology ·M. Saunders, Eric Van Cutsem, R. Wilson, Marc Peeters, Ryan P. Smith, A. Godwood, S. Oliver	3
13	First and final report of a phase II study of the poly(ADP-ribose) polymerase (PARP) inhibitor, AG014699, in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM) 2006 ·Journal of Clinical Oncology ·Ruth Plummer, Paul Lorigan, Jonathan J. Evans, Neil Steven, Mark R. Middleton, R. Wilson, Kathy J. Snow, R. Dewji, Hilary Calvert	82
14	A phase II study of the poly(ADP-ribose) polymerase (PARP) inhibitor, AG014699, in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM) 2006 ·Melanoma Research ·Ruth Plummer, (unknown), Jonathan J. Evans, Neil Steven, Mark R. Middleton, R. Wilson, R. Dewji, Kathy J. Snow, (unknown)	5
15	Final clinical, pharmacokinetic and pharmacodynamic results of the phase I study of the novel poly(ADP-ribose)polymerase (PARP) inhibitor, AG014699, in combination with temozolomide 2005 ·Clinical Cancer Research ·E. Ruth Plummer, Mark R. Middleton, R. Wilson, James Evans, Cheryl Jones, Amanda M. Olson, Alan V. Boddy, Nicola J. Curtin, (unknown), Adrian L. Harris, Peter J. Johnston, Newell, L Robson, R. Dewji, A H Calvert	6
16	First in human phase I trial of the PARP inhibitor AG-014699 with temozolomide (TMZ) in patients (pts) with advanced solid tumors 2005 ·Journal of Clinical Oncology ·Ruth Plummer, Mark R. Middleton, R. Wilson, Christopher J. Jones, Jeffrey Evans, L Robson, Heidi Steinfeldt, (unknown), Steven D. Reich, AH Calvert	37
17	A phase Ib trial of erlotinib (E) in combination with docetaxel (D) and carboplatin (C) in untreated ovarian, fallopian tube and primary peritoneal cancers 2004 ·Journal of Clinical Oncology ·P. Vasey, S.B. Kaye, James Paul, Gordon Rustin, R. Wilson, Jean‐Paul Guastalla, Éric Pujade-Lauraine, Martin Gore, Hani Gabra, Karen Carty	10
18	Erp1p and Erp2p, Partners for Emp24p and Erv25p in a Yeast p24 Complex 1999 ·Molecular Biology of the Cell ·Martina Marzioch, (unknown), Johannes M. Herrmann, R. Wilson, David Y. Thomas, John Bergeron, Roberto Solari, Adele Rowley	158
19	Monocyte chemoattractant protein-1: receptor interactions and calcium signaling mechanisms 1996 ·Journal of Leukocyte Biology ·M. Needham, Nicholas C. Sturgess, (unknown), (unknown), (unknown), R. Wilson, Loı̈c Martin, Derek Barratt, M. Anderson, C Reilly, Michael Hollis	10
20	Interleukin-2 receptor and ovarian cancer 1993 ·British Journal of Cancer ·(unknown), Clifford C. Taggart, R. Wilson, James J. Walker, (unknown), (unknown)	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact